We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

RWE studies are increasingly recognized as a regulatory pathway which accelerates the time taken to treat patients with urgent and unmet needs. It has been successfully used throughout history for the licensing of medicines, notably the development of Covid-19 vaccines and a number of cancer treatments.

RWE is at the forefront of our regulatory strategy as we seek to deliver on our goal of receiving marketing authorisations for our medicines.

We utilise existing clinical infrastructure, through collaborations with research institutions, hospital centres and government agencies, to deliver and improve patient access to our treatments.

KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, we will address broader mental health concerns reported to affect over a billion people worldwide.

We are a publicly-traded company listed on the Canadian Securities Exchange (CSE:ABRT) and Frankfurt Stock Exchange (FSE:VB50).

First biopharmaceutical company leveraging established, accelerated pathways to psychedelic-assisted therapies for patients with urgent, unmet needs across the UK, EU and other healthcare networks.

Developing scalable solutions to generate clinical data through access to existing patient pools within world-leading research and clinical networks.

Initial focus on treating cancer-related anxiety and depression before moving into broader mental health indications.

  #

Cancer-related anxiety & depression prevalence #

Cancer-related anxiety & depression is a condition characterized by a persistent feeling of uncertainty and worry, as well as sadness and heightened negative emotions. This is a chronic, relapsing, recurring and serious mental health condition associated with high mortality rates, diminished quality of life and existential crisis. The World Health Organization, or WHO, estimates that more than 500 million people worldwide are suffering from anxiety & depression.

In the UK alone there are 3 million patients suffering from cancer and of those, it is suggested that 40% suffer from severe anxiety & depression. Due to the limitations of existing treatments patients are not adequately helped.

Currently, there is no specific guidance for the treatment of cancer-related anxiety. For the treatment of generalised anxiety disorder, NICE recommends the selective serotonin reuptake inhibitor (SSRI) sertraline as the most cost-effective treatment in primary care. Given an inadequate response to sertraline, other SSRIs (e.g. escitalopram, paroxetine) or selective noradrenergic reuptake inhibitors (SNRIs; e.g. venlafaxine, duloxetine) may be offered. Pregabalin is suggested as an alternative treatment option with prescription of propranolol, buspirone and quetiapine also available. Benzodiazepines may only be used for the management of a short-term crisis due to the risk of abuse and withdrawal syndrome (Busto et al., 1986; Tyrer et al., 1981).

In addition to being relatively ineffective and having severe side-effects, they often can often cause contraindications, so it’s been shown that patients may benefit from other treatment options including psychotherapy, group therapy, family therapy, participating in self-help groups, hypnosis, and relaxation techniques such as guided imagery (a form of focused concentration on mental images to assist in stress management), or biofeedback.